ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 1 filers reported holding ASCENDIS PHARMA A/S in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $516,799 | +3.1% | 5,519 | -1.7% | 0.01% | +10.0% |
Q2 2023 | $501,317 | -20.6% | 5,617 | -4.6% | 0.01% | -23.1% |
Q1 2023 | $631,204 | -15.8% | 5,887 | -4.1% | 0.01% | -13.3% |
Q4 2022 | $750,000 | -54.1% | 6,141 | -61.2% | 0.02% | -55.9% |
Q3 2022 | $1,633,000 | +4.9% | 15,816 | -5.6% | 0.03% | +13.3% |
Q2 2022 | $1,557,000 | -20.9% | 16,749 | -0.1% | 0.03% | 0.0% |
Q1 2022 | $1,968,000 | -10.0% | 16,771 | +3.2% | 0.03% | -3.2% |
Q4 2021 | $2,186,000 | -7.4% | 16,251 | +9.7% | 0.03% | -13.9% |
Q3 2021 | $2,360,000 | +19.4% | 14,808 | -1.4% | 0.04% | +24.1% |
Q2 2021 | $1,976,000 | +11.3% | 15,020 | +9.0% | 0.03% | +3.6% |
Q1 2021 | $1,776,000 | +25.1% | 13,780 | +61.9% | 0.03% | +21.7% |
Q4 2020 | $1,420,000 | +100.3% | 8,513 | +85.2% | 0.02% | +76.9% |
Q3 2020 | $709,000 | +18.8% | 4,597 | +13.9% | 0.01% | +8.3% |
Q2 2020 | $597,000 | +295.4% | 4,037 | +200.4% | 0.01% | +200.0% |
Q1 2020 | $151,000 | – | 1,344 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |